Verrica Pharmaceuticals Inc. (VRCA)Healthcare | Biotechnology | West Chester, United States | NasdaqCM
5.69 USD
+0.62
(12.229%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.65 -0.04 (-0.040%) ⇩ (Aug. 28, 2026, 7:46 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:23 a.m. EDT
The immediate outlook is clouded by severe technical weakness and deteriorating fundamentals. The stock has lost nearly 97% of its value over the past seven years, with the most recent annual performance showing an 80% drop. While analysts maintain a 'Strong Buy' rating with a mean target of $14.80—implying significant upside potential—the current price action tells a different story. The stock is trading well below its 50-day and 200-day moving averages, indicating persistent selling pressure and a lack of near-term momentum. Recent news highlights a critical pivot point: while clinical progress continues with patient dosing in pivotal trials, the company reported a substantial Q1 loss that challenges profitability narratives. With negative operating cash flow, shrinking revenues, and no dividend history, the business remains in a high-risk, capital-intensive phase. The disconnect between the optimistic analyst consensus and the brutal price trajectory suggests the market is deeply skeptical of the path to commercialization or cost control. Until the stock can demonstrate a sustained recovery in price or a definitive turnaround in profitability, the risk-reward profile remains skewed toward caution. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.086669 |
| AutoETS | 0.140288 |
| AutoARIMA | 0.140293 |
| MSTL | 0.145105 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 6.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.149 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 42.025 |
| Revenue per Share | 1.831 |
| Market Cap | 97,747,304 |
| Forward P/E | -3.86 |
| Beta | 1.49 |
| Profit Margins | -102.84% |
| Website | https://www.verrica.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.052336454 |
| Address1 | 44 West Gay Street |
| Address2 | Suite 400 |
| All Time High | 232.9 |
| All Time Low | 3.28 |
| Ask | 6.54 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 136,040 |
| Average Daily Volume3 Month | 55,219 |
| Average Volume | 55,219 |
| Average Volume10Days | 136,040 |
| Beta | 1.493 |
| Bid | 5.33 |
| Bid Size | 1 |
| Book Value | 0.251 |
| City | West Chester |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.69 |
| Current Ratio | 1.454 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.81 |
| Day Low | 5.01 |
| Debt To Equity | 42.025 |
| Display Name | Verrica Pharmaceuticals |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,600,000 |
| Earnings Timestamp Start | 1,794,600,000 |
| Ebitda | -25,964,000 |
| Ebitda Margins | -0.8563 |
| Enterprise To Ebitda | -3.403 |
| Enterprise To Revenue | 2.914 |
| Enterprise Value | 88,359,296 |
| Eps Current Year | -2.00667 |
| Eps Forward | -1.47333 |
| Eps Trailing Twelve Months | -1.9 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.5203 |
| Fifty Day Average Change | 0.16970015 |
| Fifty Day Average Change Percent | 0.03074111 |
| Fifty Two Week Change Percent | -5.2336454 |
| Fifty Two Week High | 9.821 |
| Fifty Two Week High Change | -4.131 |
| Fifty Two Week High Change Percent | -0.42062926 |
| Fifty Two Week Low | 3.28 |
| Fifty Two Week Low Change | 2.41 |
| Fifty Two Week Low Change Percent | 0.7347561 |
| Fifty Two Week Range | 3.28 - 9.821 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,069,400,000 |
| Float Shares | 7,854,485 |
| Forward Eps | -1.47333 |
| Forward P E | -3.8619998 |
| Free Cashflow | -9,037,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 76 |
| Fullday Change | 0.62 |
| Fullday Change Percent | 12.2288 |
| Fullday Price | 5.65 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.3768 |
| Gross Profits | 11,425,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.48997003 |
| Held Percent Institutions | 0.27144 |
| Implied Shares Outstanding | 17,178,787 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,753,401,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. |
| Long Name | Verrica Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 97,747,304 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_319720251 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -31,183,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 88,814,323 |
| Number Of Analyst Opinions | 5 |
| Open | 5.12 |
| Operating Cashflow | -13,347,000 |
| Operating Margins | -1.9445599 |
| Payout Ratio | 0.0 |
| Phone | 484 453 3300 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -0.702987 |
| Post Market Price | 5.65 |
| Post Market Time | 1,787,960,765 |
| Previous Close | 5.07 |
| Price Eps Current Year | -2.8355434 |
| Price Hint | 2 |
| Price To Book | 22.669325 |
| Price To Sales Trailing12 Months | 3.2237494 |
| Profit Margins | -1.02843 |
| Quick Ratio | 0.993 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.62 |
| Regular Market Change Percent | 12.2288 |
| Regular Market Day High | 5.86 |
| Regular Market Day Low | 5.01 |
| Regular Market Day Range | 5.01 - 5.86 |
| Regular Market Open | 5.12 |
| Regular Market Previous Close | 5.07 |
| Regular Market Price | 5.69 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 350,760 |
| Return On Assets | -0.43982 |
| Revenue Growth | -0.539 |
| Revenue Per Share | 1.831 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 17,178,786 |
| Shares Percent Shares Out | 0.015700001 |
| Shares Short | 269,349 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 315,760 |
| Short Name | Verrica Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0305 |
| Short Ratio | 6.96 |
| Source Interval | 15 |
| State | PA |
| Symbol | VRCA |
| Target High Price | 20.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 14.8 |
| Target Median Price | 13.0 |
| Total Cash | 11,198,000 |
| Total Cash Per Share | 0.652 |
| Total Debt | 1,810,000 |
| Total Revenue | 30,321,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.20725 |
| Two Hundred Day Average Change | -0.51725006 |
| Two Hundred Day Average Change Percent | -0.08332998 |
| Type Disp | Equity |
| Volume | 350,760 |
| Website | https://www.verrica.com |
| Zip | 19,380 |